Peer Review History
Original SubmissionJanuary 12, 2022 |
---|
PONE-D-22-01112Single-nucleus RNA-sequencing in pre-cellularization Drosophila melanogaster embryosPLOS ONE Dear Dr. Albright, Thank you for submitting your manuscript to PLOS ONE. Your study has now been evaluated by two reviewers. As you will see both reviewers find your work of interest but also raise several points that would need to be addressed before publication can be considered. The reviewers point out in their comments where clarifications are needed and additional analysis would be required for further supporting your conclusions. I therefore, return your manuscript to you for a revision. Please, note that the revised version will be sent to the reviewers and a decision for publication made on their assessment. Please submit your revised manuscript by Apr 02 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Anton Wutz Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2. Thank you for stating the following in the Competing Interests section: "I have read the journal's policy and the authors of this manuscript have the following competing interests: MBE is a founder and former member of the board of directors of PLOS." Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, by including the following statement: "This does not alter our adherence to PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests). If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared. Please include your updated Competing Interests statement in your cover letter; we will change the online submission form on your behalf. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: No ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: No ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: No ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: This study presents results of single-nucleus RNA-sequencing (snRNA-seq) in early fly embryos undergoing zygotic genome activation. Wildtype (WT) and CTCF[mat-] mutants lacking maternal CTCF were both analyzed. Transcripts detected in single WT nuclei could be mapped onto a virtual reference embryo using known marker genes, and recapitulated known spatial expression patterns similarly to single-cell RNA-seq (Karaiskos et al. 2017). Differential gene expression between WT and CTCF[mat-] embryos was analyzed. Measuring transcript abundance differences between individual snRNA-seq clusters in WT and mutant embryos identified more differentially expressed genes than measuring transcript abundance differences between all cells of WT and mutant embryos in bulk. These results are interesting because they show that snRNA-seq is sensitive enough to detect relatively subtle gene misexpression defects in mutant embryos lacking major defects in cell fate decisions. The data appears to be of high quality. But I have 2 major confusions about the study’s design that must be addressed prior to publication (see major comments). Major comments: 1. Please clearly describe whether the CTCF[mat-] embryos generated in this study zygotically express CTCF, and discuss whether this confounds analyses of differential gene expression in CTCF[mat-] embryos if these embryos already initiated zygotic transcription. 2. I am confused by line 59. How can snRNA-seq help understand how gene expression is established prior to zygotic genome activation? If the zygotic genome is not transcribed, what would snRNA-seq detect? 3. Fig. S1 is missing. Minor comments 4. Line 40 is not well written: “Much of the difficulty in understanding the regulation of early embryonic gene expression lies in our ability [in the challenge?] to simultaneously capture expression level and patterning”. 5. Line 74-75: Kaushal et al. 2021 Nat Comm report differentially expressed genes in CTCF mutants lacking maternal and zygotic CTCF relative to WT by RNA-sequencing. This seems contradictory with the statement that differential gene expression in CTCF mutants has “not been found via sequencing”. 6. Lines 80-81: “Differential expression in spatial regions by sequencing” was previously performed by the references cited in the introduction, and therefore stating that this “was previously only possible by mechanical manipulation” should be toned down. 7. Line 169 must be amended (“nuclei ranked below the to the expected number of nuclei”). 8. Line 206: Figure references have typos. 9. Lines 218 and 220: First words of sentences should be capitalized. 10. I did not understand the meaning of the sentence in lines 234-236. 11. Cluster 9 should be discussed further, even if its spatial identity could not be determined. Why is this cluster only detected in WT but not CTCF[mat-] embryos? 12. Fig. S4 panel C is not described in the figure legend. Reviewer #2: The authors Albright et al classified embryonic nuclei by single-nucleus RNA-seq and examined CTCF-regulated gene expression in these nuclei by comparing wild type to CTCF maternal null mutants during zygotic genome activation. They identified more cluster-specific differential expression than in bulk RNA-seq and highlighted several examples of differential expression of spatial marker genes in specific clusters. The work should be of general interest. However, the data requires further analyses, and the conclusions were not clearly presented or fully supported. Major revisions are needed to both the analyses and writing. 1. Figure numbering is incorrect for all supplementary figures, and it is not possible to understand which figures the authors were calling for. The intended Figure S1 is missing. There is no Figure S9 in the submission. 2. The authors should indicate whether there is zygotic CTCF expression in this mutant. A diagram will be very helpful. The missing Figure S1 makes it more challenging to understand the properties of this KO. 3. Although the CTCF maternal knockout is known to be viable, dysregulation of Hox gene expression has been reported in embryos. The authors should characterize their new mutants and compare with previous data (Gambetta and Furlong, 2018) to report consistent or distinct phenotypes, e.g., viability and expression pattern of Hox genes. 4. Figure 1B indicates loss of cluster 9 in CTCF maternal KO. Is this because the cells are absent or because their gene expression changes and they are classified into other clusters? This can be determined by in situ of cluster 9-specific genes. 5. What is the accuracy of spatial prediction based on the RNA-seq? How many top marker genes were checked, and how many have consistent expression patterns with the in situ data? 6. The authors should verify their knockout by western blots, which are mentioned but not presented. 7. The authors stated that spatial identities cannot be assigned to clusters 8 and 9, but some quick searches with gene IDs in Figure 1C identified embryonic CNS for cluster 8 (maybe 9) and another clear distinct spatial pattern for cluster 9. The authors need to dig deeper into the spatial identity by searching more genes in those clusters using publicly available data. http://www.flyexpress.net/search/genes/CG2233/images/BDGP/LDVO http://www.flyexpress.net/search/genes/CG2225/images/BDGP/LDVO http://www.flyexpress.net/search/genes/CG3408/images/BDGP/LDVO 8. The authors need to indicate how much overlap there is between differential expression of different clusters. For example, cluster 9 has ~170 DE, cluster 3 has ~80 DE, but the common DE between clusters 3 and 9 is ~20 genes. Does this mean that most DE genes are cluster-specific? The authors need to quantify and present the data clearly. It is extremely hard to decipher the information presented in current Figure 3A. 9. The authors concluded that they identified more cluster-specific DE than in bulk but did not present data beyond the information in Figure 3A, horizontal bars. Do these bars include primarily the same genes, or they are totally different genes? It is very unclear how many more genes are detected as cluster-specific than in bulk. The authors state on page 12, “Many other genes are also differentially expressed in groups of clusters, but not in bulk.” This is very important and quantifiable information, and the authors need to present the data clearly. 10. The authors need to verify their RNA-seq data with another type of assay, e.g., RNA FISH. The differential expression (e.g., Figure 3B and C) should be verified between wildtype vs. CTCF KO cells, and between wildtype clusters of cells. Without such verification, it is hard to conclude that the single nucleus RNA-seq provides useful information. The verification should be done at least for the top differences. 11. How do the authors explain that most DE is up-regulation? Does this agree with Kaushal et al., 2021? It seems likely that decreases in DE are still masked by the inability to further separate cell types using this approach. 12. Lines 269-272: “Because we found many differentially expressed genes, we considered that this may be due to low expression given the sparsity of single-nucleus RNA-sequencing; however, we found that the mean expression of differentially expressed genes in single or multiple clusters overall does not have a substantially different pattern from that of non-differentially expressed genes.” The authors should compare and present mean expression of differential genes versus non-differential genes. This analysis is essential to rule out the possibility that more differential genes in cluster data than bulk data result from inaccurate quantification due to insufficient sequencing and coverage. Figure S9 may contain such information but is currently missing. The authors should also clearly define what they mean by “a substantially different pattern”. 13. Figure 3B-D: the expression change of patterning markers may lead to morphogenesis defects – did the authors examine the tissue morphology and distribution of marker gene expression by in situ or RNA FISH in embryos/larvae? Is the difference caused by strong differences in a small group of cells or weak differences in all cells in one cluster? 14. What are the most affected factors and signaling pathways in CTCF KO? How many of these genes are CTCF binding targets based on published CTCF ChIP-seq? 15. Please finish the sentence in lines 141, 169 (“to” and “the expected number of *UMI*”?). ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
Revision 1 |
PONE-D-22-01112R1Single-nucleus RNA-sequencing in pre-cellularization Drosophila melanogaster embryosPLOS ONE Dear Dr. Albright, Thank you for submitting your revised manuscript to PLOS ONE. Your revision has now been reevaluated by one of the original reviewers. As you will see the reviewer feels that your revision has further improved your study. There are a few points that would need to be addressed before publication can be considered. This likely would need no further experiments but changes to the conclusions and positioning of your study. If you would be able to address the remaining points and send a further revised version of your manuscript along with a point-to-point response to the reviewer's points I would be in the position to make a decision on publication. Please submit your revised manuscript by Jul 14 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Anton Wutz Academic Editor PLOS ONE Journal Requirements: Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: (No Response) ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: Most of my comments were addressed by the revisions, except for a few points below to be clarified. 1. Lines 212-213: Related to my original points 1+2, this sentence could cause confusion if the reader interprets this as meaning that snRNA-seq was performed prior to zygotic genome activation. In this study, snRNA-seq was performed on embryos undergoing zygotic genome activation; therefore, dCTCF[mat-/-] embryos probably transcribe CTCF mRNA (this could be verified in the snRNA-seq data) but do not translate (at least high levels of) CTCF protein yet. This could be explained more clearly. 2. Lines 56-60: Related to my original point 6, I feel that the authors should tone down their argument that previous scRNA-seq studies may not have primarily measured zygotic expression due to the presence of maternal cytoplasmic RNAs in cells. The present study, Karaiskos et al. 2017, and Ing-Simmons et al. 2021 likely all handled nuclei instead of cells because embryos were dounce-homogenized in all three studies – resulting in nuclei, not intact cells. In my view, the information obtained by snRNA-seq and scRNA-seq in fly embryos is thus comparable (if the authors don’t agree, please explain why). The novelty of the current study is, in my view, rather the demonstration that snRNA-seq is sensitive enough to detect relatively subtle gene misexpression defects in mutant embryos lacking major defects in cell fate decisions. 3. Line 317: “Embryonic” should be changed to “larval”, as RNA-seq was performed on central nervous systems of third instar larvae (not embryos) in Kaushal et al. 2021. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
Revision 2 |
Single-nucleus RNA-sequencing in pre-cellularization Drosophila melanogaster embryos PONE-D-22-01112R2 Dear Dr. Albright, thank you for sending your further revised manuscript. I have now read through your revision and answers to the remaining points raised by reviewer 1. Your revision has succeeded to address all remaining concerns in a satisfactory manner and your study is now scientifically suitable for publication. Your manuscript will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Anton Wutz Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: |
Formally Accepted |
PONE-D-22-01112R2 Single-nucleus RNA-sequencing in pre-cellularization Drosophila melanogaster embryos Dear Dr. Albright: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Anton Wutz Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .